Brand-name versus compounded GLP-1 cost — compared honestly
Brand-name and compounded GLP-1 programs are never ranked against each other on this site because they are different products with different regulatory standing: FDA-approved medications with reviewed manufacturing versus non-FDA-approved pharmacy preparations. What can be compared honestly is total out-of-pocket structure — list prices, manufacturer cash-pay programs such as LillyDirect and NovoCare, insurance coverage, and compounded program pricing — each labeled with what the money actually buys.
The cost layers
- Brand list price is rarely what insured patients pay; coverage, deductibles, and manufacturer savings programs change the number entirely. Uninsured cash payers should check manufacturer direct-access programs before assuming the list price applies.
- Manufacturer cash-pay programs (LillyDirect, NovoCare Pharmacy and related direct-access options) sell FDA-approved product at negotiated self-pay prices. These are covered as access guides here, never ranked alongside compounded telehealth programs.
- Compounded program pricing in the captured data runs roughly $145–$297 per month effective for semaglutide injections depending on provider, commitment, and membership structure — but the product is not FDA approved, per-order pharmacy identity often isn't confirmed up front, and dose surcharges can break "flat price" assumptions. See the semaglutide and tirzepatide comparisons for statuses.
Price alone is the wrong axis for this decision: regulatory standing, pharmacy verifiability, insurance eligibility, and a prescriber's judgment about clinical need all belong in it. Talk to a licensed clinician before choosing either path.